Proteomics

Dataset Information

0

Unperturbed dormancy recording reveals stochastic awakening strategies in endocrine treated breast cancer cells


ABSTRACT: Hormone dependent breast cancer (HDBC) is the most commonly diagnosed tumor type in women. Adjuvant endocrine therapies (ET) have been the cornerstone in the clinical management of HDBC patients for over forty years. A vast proportion of HDBC patients incur long periods of clinical dormancy following ET, with tumour awakening appearing at a steady pace for up to 25 years (Pan et al., 2017). Extensive genomic studies have demonstrated that 15-30% of clinical relapses develop recurrent genomic changes which contribute to drug resistance (i.e. ESR1 activating mutations) (Bertucci et al., 2019; Magnani et al., 2017; Razavi et al., 2018). However, even in these cases, there is no conclusive evidence around the pre-existence vs. de novo nature of these events. Here, we analyzed histone PTMs in dormant and awakened breast cancer cells treated with endocrine therapy.

INSTRUMENT(S): Q Exactive HF

ORGANISM(S): Homo Sapiens (human)

DISEASE(S): Breast Cancer

SUBMITTER: Roberta Noberini  

LAB HEAD: Tiziana Bonaldi

PROVIDER: PXD038030 | Pride | 2024-05-23

REPOSITORIES: Pride

Dataset's files

Source:
Action DRS
HF220914_RN_Magnani_1.raw Raw
HF220914_RN_Magnani_10.raw Raw
HF220914_RN_Magnani_12.raw Raw
HF220914_RN_Magnani_15.raw Raw
HF220914_RN_Magnani_19.raw Raw
Items per page:
1 - 5 of 46
altmetric image

Publications


Patients with estrogen receptor-positive breast cancer receive adjuvant endocrine therapies (ET) that delay relapse by targeting clinically undetectable micrometastatic deposits. Yet, up to 50% of patients relapse even decades after surgery through unknown mechanisms likely involving dormancy. To investigate genetic and transcriptional changes underlying tumor awakening, we analyzed late relapse patients and longitudinally profiled a rare cohort treated with long-term neoadjuvant ETs until progr  ...[more]

Similar Datasets

2024-02-14 | PXD040937 | Pride
2023-07-17 | PXD043830 | Pride
2021-02-09 | PXD014328 | Pride
2019-10-31 | E-MTAB-8318 | biostudies-arrayexpress
2022-09-21 | GSE198820 | GEO
2024-08-10 | PXD043497 | Pride
2021-04-07 | E-MTAB-9242 | biostudies-arrayexpress
2020-11-10 | GSE158578 | GEO
2022-02-28 | PXD002352 | Pride
2020-07-21 | PXD015969 | Pride